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Introduction: The efficacy of high-dose (1250 mg/d) gefitinib for
the treatment of leptomeningeal metastasis in a patient with lung
cancer harboring a mutation in the epidermal growth factor receptor
(EGFR) gene was previously reported. We speculate that erlotinib,
instead of high dose of gefitinib, may be also effective for the
treatment of central nervous system (CNS) lesions, as trough serum
concentration of erlotinib is nine times higher than that of gefitinib.
Patients and Methods: Patients with lung cancer in whom CNS
lesions developed after an initial good response to gefitinib for extra
CNS lesions were enrolled in the study. Tumor response, perfor-
mance status, neurologic symptoms, and survival were retrospec-
tively evaluated.
Results: All seven patients had EGFR mutations in their primary
tumors except one patient. The median interval between gefitinib
withdrawal and erlotinib administration was 5 days. Three patients
showed partial response, three had stable disease, and one had
progressive disease. Performance status and symptoms improved in
five patients. The overall survival from the initiation of erlotinib
treatment ranged from 15 to 530 days (median, 88 days).
Conclusions: Erlotinib was a reasonable option for the treatment of
CNS diseases that appeared after a good initial response of extra
CNS disease to gefitinib.
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Tyrosine kinase inhibitors (TKIs) of the epidermal growthfactor receptor (EGFR) have been widely used for the
treatment of patients with non-small cell lung cancer
(NSCLC). Somatic activating mutations of the tyrosine ki-
nase domain of the EGFR gene are highly associated with
sensitivity of NSCLC to EGFR TKIs.1–4 Nevertheless, the
disease in the majority of these patients eventually progresses,
despite an initial dramatic response to treatment, after a median
of about 10 months.5,6 The central nervous system (CNS), e.g.,
the brain or the leptomeninges, is a common site for metastasis
of NSCLC. Patients with CNS metastasis in general suffer from
deterioration of performance status (PS) and therefore do not
have a long-survival time. Although the recent advent of radio-
surgery techniques confers better local control of brain metas-
tases, currently there is no efficient method of treatment for
leptomeningeal metastases.
High-dose gefitinib (1250 mg/d) was reportedly effective
for the treatment of leptomeningeal metastasis in a patient with
lung cancer harboring an EGFR mutation.7 In this study, the
gefitinib concentration in the cerebrospinal fluid (CSF) was 6.2
nM at a dose of 500 mg daily, whereas it was 39 nM at a dose
of 1250 mg daily, with a serum concentration of 3730 nM. On
the other hand, the median IC50 value of cell lines that carry an
activating mutation of the EGFR gene is 90 nM.8 This difference
in concentration between the serum and the CSF is thought to be
associated with the blood–brain barrier (BBB).
Erlotinib is also an anilinoquinazoline compound
that specifically inhibits EGFR tyrosine kinase, similarly
to the action of gefitinib. Its dose was set at 150 mg daily,
which equals to the maximum tolerated dose (MTD) of this
drug. Trough serum concentration of erlotinib (adminis-
tered at 150 mg/d) is 3.5 M that is nine times higher than
that of gefitinib (0.4 M) administered at the usual dose of
250 mg/d,9–13 approximately one third of the MTD of
gefitinib (700 mg/d).
Prompted by these observations, we speculated that
erlotinib, instead of a high dose of gefitinib, may also be
effective for the treatment of CNS lesions in patients with
NSCLC harboring EGFR mutations who showed an initial good
response to gefitinib. We report the response of brain and
leptomeningeal metastases to erlotinib in seven of these patients.
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PATIENTS AND METHODS
Patients
The records of 43 patients with NSCLC that was
pathologically diagnosed and treated with erlotinib at our
institution between April 2005 and September 2008 were
retrospectively reviewed in this study. We identified those
who had been treated with erlotinib for CNS lesions that
developed after an initial good response of their extra CNS
lesions to gefitinib. This study was approved by the institu-
tional review board of the Aichi Cancer Center Hospital, and
written informed consent for genetic analysis was obtained
for each patient at the time of diagnosis or operation.
Treatment and Response Evaluation
Medical records, serum carcinoembryonic antigen
(CEA) levels, chest radiograph, chest–abdominal computed
tomography scan, brain magnetic resonance imaging (MRI),
and 18F-fluorodeoxyglucose positron emission tomography
(PET) were retrospectively reviewed. Erlotinib of 150 mg
daily were administered to the patients until progressive
disease. They all had previously received 250 mg gefitinib
daily. Treatment response was evaluated according to the
RECIST. Because of retrospective nature of this study, strict
application of RECIST was impossible. Nevertheless, we
defined tumor response when the long axis of the target lesion
shrank by more than 30%.
Mutational Analysis
We extracted RNA or DNA from tumor samples and
analyzed EGFR mutations as previously reported.5,14 Briefly,
we performed direct sequencing of the product of the reverse
transcription polymerase chain reaction of exons 18 to 21 of
the EGFR gene.
RESULTS
We identified seven patients who met our criteria. Patient
characteristics and clinical courses are summarized in Table 1.
There were five women and two men, and their ages ranged
from 58 to 81 years (median, 61 years). We confirmed the
presence of EGFR mutations in the primary tumors of all
patients, with the exception of one patient, for whom a tumor
specimen was not available. Four patients had a deletion
mutation in exon 19, and two had a point mutation in exon 21
(L858R). Six patients had been locally pretreated with whole
brain radiation therapy or radiosurgery, before disease pro-
gression in CNS.
Disease outside of the CNS was initially controlled by
gefitinib monotherapy in all seven patients. The median
duration of gefitinib administration was 310 days (range,
113–1211 days), and all patients showed progressive disease
in their CNS; four patients exhibited disease progression in
the CNS, and the other three patients developed new symp-
tomatic brain or leptomeningeal metastases associated with
deterioration of PS. Disease outside of CNS had been under
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1 81/M Adeno X19del Brain, bone CR 275 PD (new LMM) Dysmnesia, gait disorder
2 63/F Adeno X19del Lung, skin, Med LN PR 516 PD (new brain) Consciousness disorder
3 58/F Adeno L858R Brain, lung SD 113 PD (new LMM) Headache, postural disorder
4 60/F Adeno X19del Brain, bone SD 1211 PD (new LMM) Syncope, polyopia
5 64/M Adeno NA Brain, lung PR 192 PD Consciousness disorder,
gait disorder
6 60/F Adeno L858R Brain, bone NA 242 PD Dysmnesia, gait disorder
7 61/F Adeno X19del Bone, Med LN CR 382 PD (new LMM) Headache, vomiting
G, gefitinib; E, erlotinib; Med LN, mediastinal lymph nodes; TTF, time to treatment failure; CR, complete response; PR, partial response; SD, stable disease; PD, progression
disease; NA, not available; LMM, leptmeningeal metastasis.
TABLE 2. Erlotinib Treatment in Patients with CNS Involvement
Case
Interval Between










Start and Death, d
Adverse
Effects
1 35 PR 43 4 Improved 43.63 11.5 178 Rash, FN
2 2 SD 33 1 Improved 451.03 7.1 247 Rash
3 47 SD 43 3 Improved 67.03 47.6 60 —
4 5 PR 13 1 Improved 3429.53 1294.5 530 Rash, diarrhea
5 2 PR 33 2 Improved NA 88 Rash
6 8 SD 43 4 Progress 17.43 9.5 15 —
7 1 NA 33 4 Progress 136.73 110.8 23 —
G, gefitinib; E, erlotinib; CNS, central nervous system; PS, performance status; CEA, carcinoembryonic antigen; PR, partial response; SD, stable disease; NA, not available; FN,
febrile neutropenia.
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good control in all patients during gefitinib therapy. Gefitinib
was replaced with erlotinib without interposition of other
drugs. The duration of drug holiday ranged from 1 to 47 days
(median, 5 days). The PS in most patients at the initial
erlotinib administration was 3 or 4.
Using RECIST, we found that three patients showed
partial response, three patients remained stable disease, and
diagnostic imaging was not available for one patient (Table 2).
PS and metastasis-related neurologic symptoms improved in
five patients, whereas the remaining two patients had disease
progression. We confirmed that the CEA levels were reduced
in six patients after erlotinib administration, with the excep-
tion of one patient, for whom information on CEA level was
not available.
EGFR mutation analysis performed in a CSF sample
from the patient 7 before erlotinib treatment revealed a point
mutation in exon 20 (T790M), which is regarded as a resis-
tant mutation15,16 in addition to an exon 19 deletion mutation.
Her disease progressed rapidly, even after replacement of ge-
fitinib with erlotinib, and she died 23 days after the drug switch.
Case Report of Patient 1
The patient was an 81-year-old man who underwent left
upper lobectomy in August 2006. The tissue sample of his
primary tumor carried a deletion mutation in exon 19 of the
EGFR gene. Nevertheless, his serum CEA level was 13.9
ng/ml in March 2007. Although he was asymptomatic, his
brain MRI and PET scan revealed multiple metastases in the
brain and bone. We treated him with 250 mg of gefitinib daily
because he was elderly and had an EGFR mutation. The
serum CEA level had decreased to 6.3 ng/ml in May 2007.
We discontinued gefitinib treatment because of headache and
general fatigue at December 25, 2007. Although the PET and
computed tomography scans revealed remarkable improve-
ment of bone metastasis, the brain MRI revealed the presence
of new brain metastases (Figure 1A, B) and new leptomen-
ingeal metastasis, and the serum CEA level increased to 43.6
ng/ml in January 2008. Dysmnesia and gait disorder became
apparent, which escalated him to PS 4. Because of a difficulty
in swallowing, enteral nutrient and a daily dose of 150 mg of
erlotinib dissolved in water were administered via a nasogas-
tric tube from January 30. His dysmnesia improved within 1
month after the initiation of erlotinib treatment. MRI revealed
a remarkable improvement of brain metastasis in May 2008
(Figure 1C). His serum CEA level decreased to 11.3 ng/ml in
June 2008. He continued to take erlotinib for 178 days until
he died of pulmonary lymphangiosis on July 28, 2008.
DISCUSSION
In this study, we showed that erlotinib elicited tumor
responses and improvement of PS in three of seven patients
FIGURE 1. Contrast-enhanced T1-
weighted magnetic resonance imag-
ing (MRI) of the brain of patient 1.
A, MRI study performed 8 months
after initiation of gefitinib. A small
nodule was in the occipital lobe (ar-
row), but no lesions were recog-
nized in parietal lobe. B, The occipi-
tal lesion increased in size, and a
new lesion appeared in parietal lobe
in January 2008. C, The brain me-
tastases shrunk 4 months after the
initiation of erlotinib therapy.
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who developed CNS lesions after an initial good response of
extra CNS lesions to gefitinib. Neurologic symptoms and
serum CEA level improved in five of seven and six of six
patients, respectively. In addition, brain MRI revealed partial
response in three patients.
Gefitinib and erlotinib are similar anilinoquinazoline
compounds. Although it seems that erlotinib has a slightly
broader spectrum of kinase inhibition than gefitinib,17 they
are essentially EGFR-specific TKIs. The most prominent
difference between these two drugs is the dose setting. Al-
though the approved daily dose of erlotinib (i.e., 150 mg/d) is
equal to the MTD, the daily dose of gefitinib was set at 250
mg/d, because response and survival were not different be-
tween 250 and 500 mg of gefitinib in two phase II trials.18,19
This difference of dose setting is reflected in the differences
observed in their serum concentration. The Cmax and area
under the curve were 2120 ng/ml and 38,420 ng/h/ml for a
dose of erlotinib of 150 mg daily,12 and 307 and 5041 ng/h/ml
for a dose of gefitinib of 225 mg daily,13 respectively. The
administration of 700 mg of gefitinib resulted in Cmax and
area under the curve of 2146 ng/ml and 36.077 ng/h/ml,13
respectively. Nevertheless, several reports revealed an unsat-
isfactory disease control by erlotinib after gefitinib failure,
with response rates ranging from 9.5 to 14%.20,21 This can be
explained by the fact that the 2 common mechanisms of
acquired resistance to EGFR-TKI, i.e., T790M secondary
mutation and MET gene amplification, are both refractory to
gefitinib and to erlotinib.22
Animal studies revealed that the delivery of gefitinib to
the CNS of normal mice is hindered by the BBB.23 It is
possible that gefitinib may not have free access to the brain in
human,24 as another small, low-molecular weight TKI, ima-
tinib, is shown to have limited brain penetration.25 Hence, the
CSF concentration of gefitinib is usually much lower than
that observed in the serum.23 Although there are several
reports that gefitinib is effective for the treatment of brain
metastases of several tumors,24,26–31 these observations are
thought to be dependent on a combination of the degree of
disruption of the BBB caused by tumor invasion32 and a
sensitivity of cancer cells to the drug. Thus, dose escalation is
thought to be a reasonable strategy to circumvent the EGFR-
TKI-sensitive tumor cells that are present in the CNS.
In this study, we used 150 mg of erlotinib instead of
1250 mg of gefitinib. Even after a very short interval, erlo-
tinib conferred appreciable and meaningful clinical re-
sponses, which included the improvement of the level of
consciousness. While preparing this manuscript, Yi et al.33
reported that treatment of elrotinib or an increased dose of
gefitinib is an effective therapeutic option for selected patient
with NSCLC and leptomenigeal metastasis. This response
can be explained as follows; tumor cells in the CNS had not
previously been exposed to gefitinib and, therefore, did not
need to develop a resistance mechanism, thus remaining
sensitive to erlotinib which traversed the BBB because of its
relatively higher serum concentration compared with that of
gefitinib. In the case reported by Jackman et al., the tumors of
the lung, liver, and intestine had a T790M mutation, in
addition to the exon 19 deletion, while the T790M mutation
was not detected in the postmortem CNS tumor specimens.
Relatively short survival of patient 1 despite that the CNS
lesions responded well to erlotinib can be interpreted as
follows; gefitinib had reached to the extra CNS lesions and
acquired resistance to TKI such as T790M had already
developed. Therefore, even erlotinib could not control the
extra CNS lesions despite improvement of brain metastasis.
In patient 7, tumor cells of the CSF had a T790M
mutation after gefitinib treatment and before erlotinib admin-
istration. Her disease progressed rapidly, even after the
switch to erlotinib treatment, and the patient died 23 days
after the initiation of erlotinib administration, as could be
expected. In this case, we speculate that gefitinib could reach
the CNS, where it was able to control tumor cells for a while
initially. Nevertheless, the resistant clone carrying the T790M
mutation eventually developed during the 382 days of ge-
fitinib administration.
In conclusion, we report the effectiveness of erlotinib
for the treatment of CNS lesions after gefitinib failure. This
situation is relatively common in Japan, because there was an
interval of over 5 years between the approval of gefitinib and
erlotinib in our country.
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